Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
EVR1
MCID: EXD008
MIFTS: 72

Exudative Vitreoretinopathy 1 (EVR1)

Categories: Blood diseases, Cardiovascular diseases, Eye diseases, Genetic diseases, Neuronal diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Exudative Vitreoretinopathy 1

About this section

MalaCards integrated aliases for Exudative Vitreoretinopathy 1:

Name: Exudative Vitreoretinopathy 1 58 30 6 74
Retinopathy of Prematurity 58 12 54 60 30 6 45 15 41 17 74
Retrolental Fibroplasia 12 77 54 60
Familial Exudative Vitreoretinopathy, Autosomal Dominant 25 30
Criswick-Schepens Syndrome 58 76
Evr1 58 76
Rop 54 60
Exudative Vitreoretinopathy, Familial, Autosomal Dominant 58
Autosomal Dominant Familial Exudative Vitreoretinopathy 76
Vitreoretinopathy, Exudative, Type 1 41
Vitreoretinopathy, Exudative 1 76
Fevr, Autosomal Dominant 58
Premature Retinopathy 12
Adfevr 25
Fevr 76

Characteristics:

Orphanet epidemiological data:

60
retinopathy of prematurity
Age of onset: Infancy,Neonatal; Age of death: normal life expectancy;

OMIM:

58
Inheritance:
autosomal dominant

Miscellaneous:
clinical variability
onset in infancy or early childhood
slowly progressive disorder
some patients may be asymptomatic
absence of premature birth, low birthweight, and exposure to oxygen
genetic heterogeneity, see evr2 , evr3 , and evr4


HPO:

33
exudative vitreoretinopathy 1:
Onset and clinical course infantile onset slow progression
Inheritance autosomal dominant inheritance


GeneReviews:

25
Penetrance When using fluorescein angiography to determine clinical status, penetrance is reported to be 100% because all affected individuals have a sector of avascular peripheral retina [ober et al 1980]...

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Eye diseases Cardiovascular diseases Neuronal diseases Blood diseases
See all MalaCards categories (disease lists)
ICD10: 34 35
Orphanet: 60  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:13025
OMIM 58 133780
ICD9CM 36 362.20 362.21
MeSH 45 D012178
NCIt 51 C34982
SNOMED-CT 69 74277007
MESH via Orphanet 46 D012178
ICD10 via Orphanet 35 H35.1
UMLS via Orphanet 75 C0035344
Orphanet 60 ORPHA90050
Sources

Summaries for Exudative Vitreoretinopathy 1

About this section
OMIM : 58 Familial exudative vitreoretinopathy (FEVR) is an inherited disorder characterized by the incomplete development of the retinal vasculature. Its clinical appearance varies considerably, even within families, with severely affected patients often registered as blind during infancy, whereas mildly affected patients with few or no visual problems may have such a small area of avascularity in their peripheral retina that it is visible only by fluorescein angiography. It is believed that this peripheral avascularity is the primary anomaly in FEVR and results from defective retinal angiogenesis. The sight-threatening features of the FEVR phenotype are considered secondary to retinal avascularity and develop because of the resulting retinal ischemia; they include the development of hyperpermeable blood vessels, neovascularization, vitreoretinal traction, retinal folds, and retinal detachments (summary by Poulter et al., 2010). In 31 Chinese pedigrees clinically diagnosed with FEVR, Rao et al. (2017) analyzed 6 FEVR-associated genes and identified mutations in 12 of the probands, including 5 (16.1%) in LRP5, 3 (9.7%) in NDP, 2 (6.5%) in FZD4, and 1 (3.2%) in TSPAN12. In addition, a mutation in the KIF11 gene (148760) was identified in a patient who also exhibited microcephaly (MCLMR; 152950). The authors noted that their detection rate did not exceed 50%, suggesting that other FEVR-associated genes remained to be discovered. (133780)

MalaCards based summary : Exudative Vitreoretinopathy 1, also known as retinopathy of prematurity, is related to exudative vitreoretinopathy and retinal detachment, and has symptoms including hyperoxia An important gene associated with Exudative Vitreoretinopathy 1 is FZD4 (Frizzled Class Receptor 4), and among its related pathways/superpathways are Focal Adhesion and Ras signaling pathway. The drugs Ketorolac and Bevacizumab have been mentioned in the context of this disorder. Affiliated tissues include eye, endothelial and retina, and related phenotypes are premature birth and small for gestational age

UniProtKB/Swiss-Prot : 76 Vitreoretinopathy, exudative 1: A disorder of the retinal vasculature characterized by an abrupt cessation of growth of peripheral capillaries, leading to an avascular peripheral retina. This may lead to compensatory retinal neovascularization, which is thought to be induced by hypoxia from the initial avascular insult. New vessels are prone to leakage and rupture causing exudates and bleeding, followed by scarring, retinal detachment and blindness. Clinical features can be highly variable, even within the same family. Patients with mild forms of the disease are asymptomatic, and their only disease related abnormality is an arc of avascular retina in the extreme temporal periphery. In many ways the disease resembles retinopathy of prematurity but there is no evidence of prematurity or small birth weight in the patient history.

Wikipedia : 77 Retinopathy of prematurity (ROP), also called retrolental fibroplasia (RLF) and Terry syndrome, is a... more...

GeneReviews: NBK1147
Sources

Related Diseases for Exudative Vitreoretinopathy 1

About this section

Diseases in the Exudative Vitreoretinopathy family:

Exudative Vitreoretinopathy 1 Exudative Vitreoretinopathy 4
Exudative Vitreoretinopathy 3 Exudative Vitreoretinopathy 5
Exudative Vitreoretinopathy 6 Exudative Vitreoretinopathy 7

Diseases related to Exudative Vitreoretinopathy 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 150)
# Related Disease Score Top Affiliating Genes
1 exudative vitreoretinopathy 31.9 ARHGAP1 CTNNB1 FZD4 LRP5 NDP PRSS23
2 retinal detachment 31.0 CTNNB1 FZD4 LRP5 NDP TSPAN12 VEGFA
3 skin hemangioma 30.9 FLT1 KDR VEGFA
4 hemangioma 30.9 FLT1 KDR VEGFA
5 norrie disease 30.7 FZD4 LRP5 NDP TSPAN12
6 retinal vascular disease 30.2 FLT1 FZD4 KDR LRP5 NDP TSPAN12
7 coats disease 30.2 FZD4 KDR LRP5 NDP TSPAN12 VEGFA
8 microvascular complications of diabetes 5 30.1 FLT1 IGF1 KDR VEGFA
9 persistent hyperplastic primary vitreous 30.1 FZD4 NDP TSPAN12
10 exudative vitreoretinopathy 4 11.4
11 exudative vitreoretinopathy 3 11.4
12 exudative vitreoretinopathy 5 11.4
13 microcephaly with or without chorioretinopathy, lymphedema, or mental retardation 11.1
14 exudative vitreoretinopathy 2, x-linked 11.1
15 mental retardation with language impairment and with or without autistic features 11.0
16 microcephaly and chorioretinopathy, autosomal recessive, 1 11.0
17 cataract 10.4
18 myopia 10.4
19 leukocoria 10.4 FZD4 LRP5 NDP
20 refractive error 10.4
21 strabismus 10.4
22 mechanical strabismus 10.4
23 sudden infant death syndrome 10.4
24 yemenite deaf-blind hypopigmentation syndrome 10.3
25 osteoporosis-pseudoglioma syndrome 10.3 CTNNB1 FZD4 LRP5 NDP
26 male reproductive organ cancer 10.3 CTNNB1 IGF1 VEGFA
27 angiokeratoma circumscriptum 10.3 FLT1 KDR VEGFA
28 epithelioid hemangioendothelioma 10.3 FLT1 KDR VEGFA
29 capillary hemangioma 10.3 FLT1 KDR VEGFA
30 reproductive system disease 10.3 CTNNB1 IGF1 VEGFA
31 vascular cancer 10.2 FLT1 KDR VEGFA
32 corneal neovascularization 10.2 FLT1 KDR VEGFA
33 gastrointestinal system cancer 10.2 CTNNB1 KDR VEGFA
34 retinal telangiectasia 10.2 FZD4 NDP TSPAN12 VEGFA
35 placental insufficiency 10.2 FLT1 KDR VEGFA
36 bronchopulmonary dysplasia 10.2
37 hyperglycemia 10.2
38 angiosarcoma 10.2 FLT1 KDR VEGFA
39 glomeruloid hemangioma 10.2 FLT1 VEGFA
40 endocrine gland cancer 10.2 CTNNB1 KDR VEGFA
41 incontinentia pigmenti 10.2
42 keratoconus 10.2
43 neuromyelitis optica 10.2
44 rickets 10.2
45 choroiditis 10.2
46 congenital toxoplasmosis 10.2
47 toxoplasmosis 10.2
48 neuromyelitis optica spectrum disorder 10.2
49 adamantinous craniopharyngioma 10.2 CTNNB1 VEGFA
50 microvascular complications of diabetes 1 10.2 FLT1 IGF1 VEGFA

Graphical network of the top 20 diseases related to Exudative Vitreoretinopathy 1:



Diseases related to Exudative Vitreoretinopathy 1
Sources

Symptoms & Phenotypes for Exudative Vitreoretinopathy 1

About this section

Human phenotypes related to Exudative Vitreoretinopathy 1:

60 33 (show all 19)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 premature birth 60 33 hallmark (90%) Very frequent (99-80%) HP:0001622
2 small for gestational age 60 33 hallmark (90%) Very frequent (99-80%) HP:0001518
3 blindness 60 33 occasional (7.5%) Occasional (29-5%) HP:0000618
4 retinal arteriolar tortuosity 60 33 occasional (7.5%) Occasional (29-5%) HP:0001136
5 tractional retinal detachment 60 33 occasional (7.5%) Occasional (29-5%) HP:0007917
6 vitreous hemorrhage 60 33 occasional (7.5%) Occasional (29-5%) HP:0007902
7 abnormal macular morphology 33 occasional (7.5%) HP:0001103
8 reduced visual acuity 33 HP:0007663
9 abnormality of the macula 60 Occasional (29-5%)
10 abnormality of the retinal vasculature 60 Very frequent (99-80%)
11 retinal detachment 33 HP:0000541
12 recurrent fractures 33 HP:0002757
13 exudative vitreoretinopathy 33 HP:0030490
14 subcapsular cataract 33 HP:0000523
15 retinal exudate 33 HP:0001147
16 peripheral retinal avascularization 33 HP:0007685
17 retinal neovascularization 33 HP:0030666
18 falciform retinal fold 33 HP:0001493
19 posterior vitreous detachment 33 HP:0001489

Symptoms via clinical synopsis from OMIM:

58
Head And Neck Eyes:
blindness
vitreous hemorrhage
decreased visual acuity
falciform retinal folds
vitreoretinal traction
more
Skeletal:
low bone density
increased fracture rate

Clinical features from OMIM:

133780

UMLS symptoms related to Exudative Vitreoretinopathy 1:


hyperoxia

GenomeRNAi Phenotypes related to Exudative Vitreoretinopathy 1 according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 9.92 ARHGAP1 ATP7B CD38 CDKN1C CPVL CTNNB1

MGI Mouse Phenotypes related to Exudative Vitreoretinopathy 1:

47 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.32 ARHGAP1 ATP7B CD38 CTNNB1 EPO FLT1
2 cardiovascular system MP:0005385 10.26 CTNNB1 EPO FLT1 FZD4 IGF1 KDR
3 homeostasis/metabolism MP:0005376 10.21 ARHGAP1 ATP7B CD38 CTNNB1 EPO FLT1
4 hematopoietic system MP:0005397 10.2 ARHGAP1 ATP7B CD38 CTNNB1 EPO FLT1
5 endocrine/exocrine gland MP:0005379 10.13 ARHGAP1 ATP7B CD38 CTNNB1 FZD4 IGF1
6 embryo MP:0005380 10.1 ARHGAP1 CTNNB1 EPO FLT1 FZD4 KDR
7 immune system MP:0005387 10.1 ARHGAP1 ATP7B CD38 CTNNB1 EPO FLT1
8 integument MP:0010771 10.02 ARHGAP1 ATP7B CTNNB1 EPO FZD4 IGF1
9 muscle MP:0005369 9.96 ARHGAP1 ATP7B CTNNB1 EPO FLT1 FZD4
10 liver/biliary system MP:0005370 9.87 ARHGAP1 ATP7B CTNNB1 EPO KDR LRP5
11 normal MP:0002873 9.81 CTNNB1 EPO FLT1 FZD4 IGF1 INPP5J
12 pigmentation MP:0001186 9.35 ATP7B CTNNB1 FZD4 LRP5 NDP
13 vision/eye MP:0005391 9.23 CTNNB1 FLT1 FZD4 KDR LRP5 NDP
Sources

Drugs & Therapeutics for Exudative Vitreoretinopathy 1

About this section

Drugs for Exudative Vitreoretinopathy 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 272)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketorolac Approved Phase 4,Phase 2 74103-06-3, 66635-83-4 3826
2
Bevacizumab Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 216974-75-3
3 Poractant alfa Approved Phase 4,Not Applicable 129069-19-8
4
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 57-83-0 5994
5
Sodium Citrate Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 68-04-2
6
Caffeine Approved Phase 4,Phase 3,Phase 2,Not Applicable 58-08-2 2519
7
Indomethacin Approved, Investigational Phase 4,Phase 3,Phase 2 53-86-1 3715
8
Ibuprofen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15687-27-1 3672
9
Ketamine Approved, Vet_approved Phase 4 6740-88-1 3821
10
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
11
Nitrous oxide Approved, Vet_approved Phase 4,Phase 3 10024-97-2 948
12
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
13
Ranibizumab Approved Phase 4,Phase 3,Phase 2,Not Applicable 347396-82-1 459903
14
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 7440-70-2 271
15
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 77-92-9 311
16
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
17 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
22 Ketorolac Tromethamine Phase 4,Phase 2
23 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Omega 3 Fatty Acid Phase 4,Phase 3,Phase 2,Not Applicable
26 Soy Bean Phase 4,Phase 3,Not Applicable
27 Olive Phase 4,Phase 3,Not Applicable
28 Pulmonary Surfactants Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
29 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable
30 Central Nervous System Depressants Phase 4,Phase 3,Not Applicable
31 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
32 Angiogenesis Modulating Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
33 Angiogenesis Inhibitors Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
34 Antineoplastic Agents, Immunological Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable
35 Trace Elements Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
36 Nutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
37 Protective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
38 Micronutrients Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
39 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Respiratory System Agents Phase 4,Phase 2,Phase 3,Not Applicable
41 Phosphodiesterase Inhibitors Phase 4,Phase 2,Phase 3,Not Applicable
42 Anticoagulants Phase 4,Phase 3,Phase 2,Not Applicable
43 Chelating Agents Phase 4,Phase 2,Not Applicable
44 Central Nervous System Stimulants Phase 4,Phase 3,Phase 2,Not Applicable
45 Citrate Phase 4,Phase 2,Phase 3,Not Applicable
46 Purinergic P1 Receptor Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
47 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Caffeine citrate Phase 4,Phase 3,Phase 2,Not Applicable
49 Tocolytic Agents Phase 4,Phase 3,Phase 2
50 Pharmaceutical Solutions Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 292)
# Name Status NCT ID Phase Drugs
1 Efficient Study of ACULAR in Inhibiting Proliferative Retinopathy in Prematurity Unknown status NCT00634972 Phase 4 ACULAR;REFRESH TEARS;placebo
2 Withholding Feeds During Red Blood Cell Transfusion and TRAGI Unknown status NCT02132819 Phase 4
3 Rate of Bronchopulmonary Dysplasia in Preterms Neonates: a Trial Comparing SMOFlipid and Medialipide Unknown status NCT02853253 Phase 4
4 Cpap at Delivery Room for Preterm Infants Unknown status NCT01024361 Phase 4
5 Early CPAP in Respiratory Distress Syndrome Unknown status NCT00368680 Phase 4
6 Sucrose Analgesia for the Reduction of Pain During Retinopathy of Prematurity Screening Completed NCT00921544 Phase 4
7 Anesthesia for Retinopathy of Prematurity Completed NCT01955135 Phase 4 Ketamine;Sevoflurane;propofol
8 Vascular Endothelial Growth Factor in Stage V ROP Completed NCT00500396 Phase 4
9 VEGF Levels in Aqueous, Vitreous and Subretinal Fluid in ROP Stage IV and V Completed NCT00563121 Phase 4
10 VEGF Concentrations After Intravitreal Bevacizumab vs Ranibizumab as a Treatment for Type 1 ROP Completed NCT03148132 Phase 4 Bevacizumab Injection;Ranibizumab Ophthalmic
11 Vitamin A and Very Low Birthweight Babies (VitAL) Completed NCT00417404 Phase 4 Aquasol A;aquasol A
12 Early Versus Late Lactoferrin in Prevention of Neonatal Sepsis Completed NCT02959229 Phase 4 Lactoferrin;Placebo (for Lactoferrin)
13 OPTIMIST-A Trial: Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on CPAP Recruiting NCT02140580 Phase 4
14 Randomized Controlled Trial of Vaginal Progesterone in Women With Threatened Preterm Labor Terminated NCT01286246 Phase 4 Vaginal progesterone;Placebo
15 MRI and Neurodevelopment in Preterm Infants Following Administration of High-Dose Caffeine Completed NCT00809055 Phase 4 Caffeine citrate
16 Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
17 Personalized vs Standardized PN for Preterm Infants >1250g Not yet recruiting NCT03693287 Phase 4 Standardized-parenteral nutrition (S-PN);Personalized-parenteral nutrition (P-PN)
18 TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence Recruiting NCT02621645 Phase 4
19 Antiangiogenic Therapy With Bevacizumab in Retinopathy of Prematurity. Structural Outcome Unknown status NCT00346814 Phase 2, Phase 3 intravitreal injection
20 The Early Treatment for Retinopathy of Prematurity Study (ETROP) Unknown status NCT00027222 Phase 2, Phase 3
21 Randomized Study of Pessary Versus Standard Management in Women With Increased Chance of Premature Birth Unknown status NCT00735137 Phase 3
22 Cysteine Supplementation in Critically Ill Neonates Unknown status NCT00254176 Phase 2, Phase 3
23 Duration of Antibiotics Treatment With Cefazolin and Clarithromycin in Women With Preterm Premature Rupture of Membrane Unknown status NCT01503606 Phase 3 Cefazolin;Clarithromycin;Cefazolin;Clarithromycin
24 Efficacy and Safety of Goat Lung Surfactant for the Treatment of Respiratory Distress Syndrome in Preterm Neonates Unknown status NCT02774044 Phase 2, Phase 3 Cadisurf;Survanta
25 Modulation of the Intestinal Flora With the Probiotic VIVOMIXXâ„¢ in Pregnant Women at Risk of Metabolic Complications Unknown status NCT02768818 Phase 3
26 A Fatty Acids Study in Preventing Retinopathy of Prematurity Completed NCT02760472 Phase 3 SMOFlipid;Clinoleic
27 Inositol to Reduce Retinopathy of Prematurity Terminated NCT01954082 Phase 3 myo-Inositol 5% Injection;Placebo
28 RAINBOW Study: RAnibizumab Compared With Laser Therapy for the Treatment of INfants BOrn Prematurely With Retinopathy of Prematurity Completed NCT02375971 Phase 3 Ranibizumab
29 Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity Completed NCT01079715 Phase 2, Phase 3 Propranolol
30 Rainbow Extension Study Recruiting NCT02640664 Phase 3 Ranibizumab;Ranibizumab
31 Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity Completed NCT01203436 Phase 2, Phase 3
32 The Effects of Light Reduction on Retinopathy of Prematurity (Light-ROP) Completed NCT00000156 Phase 3
33 Inhaled Nitrous Oxide for Pain Relief During Eye Exam in the Pre-term Infant Completed NCT00623220 Phase 3
34 Surfactant Positive Airway Pressure and Pulse Oximetry Trial Completed NCT00233324 Phase 3 Surfactant;Supplemental oxygen with target saturation of 85 to 89%;Supplemental oxygen with target saturation of 91 to 95%
35 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Hypothyroxinemia Completed NCT01306227 Phase 3 L-Thyroxine;water
36 Premature Infants in Need of Transfusion (PINT) Completed NCT00182390 Phase 3
37 CLAIR -FO: Clinical Trial of Ophthalmic Insert Mydriasert® Versus Reference Treatment Terminated NCT00642135 Phase 3 Mydriasert®;phenylephrine and tropicamide eyedrops
38 Progesterone to Prevent Preterm Delivery Recruiting NCT03428685 Phase 2, Phase 3 Dydrogesterone Oral Tablet;Placebo Oral Tablet
39 A Phase III Efficacy and Safety Study of Intravenous Retosiban Versus Placebo for Women in Spontaneous Preterm Labor Terminated NCT02377466 Phase 3 Retosiban IV infusion;Placebo IV infusion
40 Antibiotics Study in Preterm Premature Rupture of the Membranes Completed NCT01401179 Phase 3 cefazolin, erythromycin, clarithromycin
41 Lactoferrin Infant Feeding Trial - LIFT_Canada Recruiting NCT03367013 Phase 3
42 Pharmacokinetics, Safety and Efficacy Study of Recombinant Antithrombin Versus Placebo in Preterm Preeclampsia Completed NCT02059135 Phase 3
43 Inhaled Nitric Oxide to Prevent and Treat Bronchopulmonary Dysplasia Completed NCT01503801 Phase 2, Phase 3 Nitric Oxide
44 Vaginal Progesterone for the Prevention of Preterm Birth in Twins Not yet recruiting NCT03540225 Phase 3 Progesterone
45 Cervical Pessary vs Vaginal Progesterone in Preventing Preterm Birth Among Women Presenting With Short Cervix: An Open-label Randomized Controlled Trial Not yet recruiting NCT02470676 Phase 2, Phase 3 Progesterone
46 Sildenafil Therapy In Dismal Prognosis Early-Onset Intrauterine Growth Restriction Terminated NCT02442492 Phase 2, Phase 3 Sildenafil;Placebo
47 Oxygen Toxicity in the Resuscitation in Extremely Premature Infants Completed NCT00494702 Phase 3
48 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3 Folic Acid 4 mg;Placebo
49 Pravastatin to Prevent Preeclampsia Not yet recruiting NCT03944512 Phase 3 Pravastatin
50 A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV) Active, not recruiting NCT01376778 Phase 3 CMV hyperimmune globulin

Search NIH Clinical Center for Exudative Vitreoretinopathy 1

Cochrane evidence based reviews: retinopathy of prematurity

Sources

Genetic Tests for Exudative Vitreoretinopathy 1

About this section

Genetic tests related to Exudative Vitreoretinopathy 1:

# Genetic test Affiliating Genes
1 Exudative Vitreoretinopathy 1 30 FZD4 LRP5
2 Retinopathy of Prematurity 30
3 Familial Exudative Vitreoretinopathy, Autosomal Dominant 30
Sources

Anatomical Context for Exudative Vitreoretinopathy 1

About this section

MalaCards organs/tissues related to Exudative Vitreoretinopathy 1:

42
Eye, Endothelial, Retina, Lung, Skin, Breast, Cervix
Sources

Publications for Exudative Vitreoretinopathy 1

About this section

Articles related to Exudative Vitreoretinopathy 1:

(show top 50) (show all 3035)
# Title Authors Year
1
Exudative Retinal Detachment Following Laser Photocoagulation for Retinopathy of Prematurity: A Rare Complication. ( 30998247 )
2019
2
A Surgical Technique for the Management of Tractional Retinal Detachment in Aggressive Posterior Retinopathy of Prematurity Treated With Intravitreal Bevacizumab. ( 30198966 )
2019
3
THROMBOCYTOPENIA AS A RISK FACTOR FOR RETINOPATHY OF PREMATURITY. ( 29370028 )
2019
4
Intravitreal Delivery of VEGF-A165-loaded PLGA Microparticles Reduces Retinal Vaso-Obliteration in an In Vivo Mouse Model of Retinopathy of Prematurity. ( 30383455 )
2019
5
Comparison of clinical outcomes of intravitreal ranibizumab and aflibercept treatment for retinopathy of prematurity. ( 30397793 )
2019
6
The severity and associated comorbidities of retinopathy of prematurity among micro-premature infants with birth weights less than 750 grams. ( 30400108 )
2019
7
Programming Error Led to Underestimate of Effect Sizes in Study of Association of Maternal Preeclampsia and Risk of Infant Retinopathy of Prematurity. ( 30422231 )
2019
8
Retinopathy of Prematurity Status: Invisible with Indirect Ophthalmoscopy but Established with Optos Ultrawide-Field Retinal Imaging. ( 30439374 )
2019
9
Early red cell transfusion is associated with development of severe retinopathy of prematurity. ( 30459388 )
2019
10
Algorithm for predicting threshold retinopathy of prematurity is insufficient and fundus examinations are still needed before 31 weeks. ( 30461053 )
2019
11
Clinical Presentation and Management Outcomes of Coexistent Congenital Glaucoma and Retinopathy of Prematurity. ( 30461550 )
2019
12
Early postnatal weight gain as a predictor for the development of retinopathy of prematurity. ( 28920494 )
2019
13
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY OF THE FOVEAL AVASCULAR ZONE IN CHILDREN WITH A HISTORY OF TREATMENT-REQUIRING RETINOPATHY OF PREMATURITY. ( 29190231 )
2019
14
Propofol and fentanyl sedation for laser treatment of retinopathy of prematurity to avoid intubation. ( 28974135 )
2019
15
Foveal microvascular anomalies on optical coherence tomography angiography and the correlation with foveal thickness and visual acuity in retinopathy of prematurity. ( 30361765 )
2019
16
A Spectrum of Regression Following Intravitreal Bevacizumab in Retinopathy of Prematurity. ( 30312578 )
2019
17
YouTube as a source of information in retinopathy of prematurity. ( 30238185 )
2019
18
A modified developmental care bundle reduces pain and stress in preterm infants undergoing examinations for retinopathy of prematurity: A randomised controlled trial. ( 30091495 )
2019
19
Automated Analysis for Retinopathy of Prematurity by Deep Neural Networks. ( 30080144 )
2019
20
Different effects of various anti-angiogenic treatments in an experimental mouse model of retinopathy of prematurity. ( 30073769 )
2019
21
Literature review informs clinical guidelines for pain management during screening and laser photocoagulation for retinopathy of prematurity. ( 30054933 )
2019
22
Efficacy of intravitreal conbercept injection in the treatment of retinopathy of prematurity. ( 30030391 )
2019
23
Systematic review and meta-analysis of the negative outcomes of retinopathy of prematurity treated with laser photocoagulation. ( 30022693 )
2019
24
Trends in the incidence of retinopathy of prematurity over a 10-year period. ( 29907928 )
2019
25
Evaluation of refractive errors in retinopathy of prematurity screening. ( 31077125 )
2019
26
Automated Fundus Image Quality Assessment in Retinopathy of Prematurity Using Deep Convolutional Neural Networks. ( 31044738 )
2019
27
Fluorescein Angiography in Retinopathy of Prematurity: Comparison of Infants Treated with Bevacizumab to Those with Spontaneous Regression. ( 31044736 )
2019
28
A computer-aided diagnosis system for plus disease in retinopathy of prematurity with structure adaptive segmentation and vessel based features. ( 31039506 )
2019
29
Imaging in Retinopathy of Prematurity. ( 31037876 )
2019
30
Increased circulation mobilization of endothelial progenitor cells in preterm infants with retinopathy of prematurity. ( 31033032 )
2019
31
Endothelial progenitor cells in preterm infants with retinopathy of prematurity. ( 31033010 )
2019
32
Asymmetry of Retinopathy of Prematurity Border in the Telemedicine Approaches to Evaluating Acute-Phase Retinopathy of Prematurity Study. ( 31014707 )
2019
33
Perinatal Risk Factors for the Retinopathy of Prematurity in Postnatal Growth and Rop Study. ( 31012360 )
2019
34
Genetic variants of TSPAN12 gene in patients with retinopathy of prematurity. ( 31009104 )
2019
35
Describing Retinopathy of Prematurity: Current Limitations and New Challenges. ( 31005186 )
2019
36
Experimental Evidence Behind Clinical Trial Outcomes in Retinopathy of Prematurity. ( 30998244 )
2019
37
Vessel Tortuosity Cutoff Values Using the Modified ROPtool May Predict Need for Treatment in Retinopathy of Prematurity. ( 30998242 )
2019
38
Long-Term Anatomic and Visual Outcome Following Vitrectomy for Stage 4B and 5 Retinopathy of Prematurity. ( 30998241 )
2019
39
Intravitreal Ranibizumab Injection for the Treatment of Retinopathy of Prematurity. ( 30995663 )
2019
40
Enhancing Retinal Endothelial Glycolysis by Inhibiting UCP2 Promotes Physiologic Retinal Vascular Development in a Model of Retinopathy of Prematurity. ( 30995317 )
2019
41
Incidence of retinopathy of prematurity type 1 and type 2 in a regional Hospital of Social Security in the state of Queretaro, Mexico (2017-2018). ( 30987639 )
2019
42
Increased incidence of retinopathy of prematurity and evolving treatment modalities at a Canadian tertiary centre. ( 30975353 )
2019
43
EARLY VITAMIN A SUPPLEMENTATION IMPROVES THE OUTCOME OF RETINOPATHY OF PREMATURITY IN EXTREMELY PRETERM INFANTS. ( 30964778 )
2019
44
Neurodevelopmental Outcomes Following Intravitreal Bevacizumab Therapy for Retinopathy of Prematurity: a prospective, case-control study. ( 30954553 )
2019
45
Retrospective Validation of the Postnatal Growth and Retinopathy of Prematurity (G-ROP) Criteria in a Japanese Cohort. ( 30954468 )
2019
46
Discovering Mechanisms in the Changing and Diverse Pathology of Retinopathy of Prematurity: The Weisenfeld Award Lecture. ( 30933256 )
2019
47
Prenatal and postnatal inflammation-related risk factors for retinopathy of prematurity. ( 30932029 )
2019
48
Association of Retinopathy of Prematurity and Plateau iris. ( 30921273 )
2019
49
Leukocytosis is associated with retinopathy of prematurity in extremely preterm infants. ( 30920014 )
2019
50
Can IL-33 and Endocan be New Markers for Retinopathy of Prematurity? ( 30914019 )
2019
Sources

Variations for Exudative Vitreoretinopathy 1

About this section

UniProtKB/Swiss-Prot genetic disease variations for Exudative Vitreoretinopathy 1:

76 (show all 23)
# Symbol AA change Variation ID SNP ID
1 FZD4 p.Met105Val VAR_038947 rs80358284
2 FZD4 p.Met157Val VAR_038948 rs80358286
3 FZD4 p.Gly36Asp VAR_063921 rs80358281
4 FZD4 p.Glu40Gln VAR_063922 rs139401671
5 FZD4 p.His69Tyr VAR_063923 rs80358282
6 FZD4 p.Met105Thr VAR_063924 rs80358285
7 FZD4 p.Ile114Thr VAR_063925
8 FZD4 p.Cys181Arg VAR_063927 rs80358287
9 FZD4 p.Cys204Arg VAR_063929 rs80358288
10 FZD4 p.Cys204Tyr VAR_063930 rs106479406
11 FZD4 p.Met223Lys VAR_063931
12 FZD4 p.Ile256Val VAR_063932 rs104894223
13 FZD4 p.Trp335Cys VAR_063933 rs80358292
14 FZD4 p.Met342Val VAR_063934 rs80358293
15 FZD4 p.Arg417Gln VAR_063936 rs80358294
16 FZD4 p.Thr445Pro VAR_063937 rs80358297
17 FZD4 p.Gly488Asp VAR_063938 rs80358298
18 FZD4 p.Ser497Phe VAR_063939 rs80358300
19 FZD4 p.Gly525Arg VAR_063940
20 LRP5 p.Arg348Trp VAR_063948 rs132006503
21 LRP5 p.Asp381Asn VAR_076548 rs133227486
22 LRP5 p.Arg624Trp VAR_076549 rs989864153
23 LRP5 p.Tyr1517Cys VAR_076550 rs201030241

ClinVar genetic disease variations for Exudative Vitreoretinopathy 1:

6 (show all 39)
# Gene Variation Type Significance SNP ID Assembly Location
1 FZD4 NM_012193.3(FZD4): c.1479_1484delGTGGAT (p.Met493_Trp494del) deletion Pathogenic rs80358301 GRCh37 Chromosome 11, 86662314: 86662319
2 FZD4 NM_012193.3(FZD4): c.1479_1484delGTGGAT (p.Met493_Trp494del) deletion Pathogenic rs80358301 GRCh38 Chromosome 11, 86951272: 86951277
3 FZD4 NM_012193.3(FZD4): c.1501_1502delCT (p.Leu501Serfs) deletion Pathogenic rs80358303 GRCh37 Chromosome 11, 86662296: 86662297
4 FZD4 NM_012193.3(FZD4): c.1501_1502delCT (p.Leu501Serfs) deletion Pathogenic rs80358303 GRCh38 Chromosome 11, 86951254: 86951255
5 FZD4 NM_012193.3(FZD4): c.1250G> A (p.Arg417Gln) single nucleotide variant Pathogenic rs80358294 GRCh37 Chromosome 11, 86662548: 86662548
6 FZD4 NM_012193.3(FZD4): c.1250G> A (p.Arg417Gln) single nucleotide variant Pathogenic rs80358294 GRCh38 Chromosome 11, 86951506: 86951506
7 FZD4 NM_012193.3(FZD4): c.1024A> G (p.Met342Val) single nucleotide variant Pathogenic rs80358293 GRCh37 Chromosome 11, 86662774: 86662774
8 FZD4 NM_012193.3(FZD4): c.1024A> G (p.Met342Val) single nucleotide variant Pathogenic rs80358293 GRCh38 Chromosome 11, 86951732: 86951732
9 FZD4 NM_012193.3(FZD4): c.1005G> C (p.Trp335Cys) single nucleotide variant Pathogenic rs80358292 GRCh37 Chromosome 11, 86662793: 86662793
10 FZD4 NM_012193.3(FZD4): c.1005G> C (p.Trp335Cys) single nucleotide variant Pathogenic rs80358292 GRCh38 Chromosome 11, 86951751: 86951751
11 FZD4 NM_012193.3(FZD4): c.766A> G (p.Ile256Val) single nucleotide variant Pathogenic rs104894223 GRCh37 Chromosome 11, 86663032: 86663032
12 FZD4 NM_012193.3(FZD4): c.766A> G (p.Ile256Val) single nucleotide variant Pathogenic rs104894223 GRCh38 Chromosome 11, 86951990: 86951990
13 ZNF408 NM_024741.2(ZNF408): c.-111C> A single nucleotide variant Uncertain significance rs796065314 GRCh37 Chromosome 11, 46722487: 46722487
14 ZNF408 NM_024741.2(ZNF408): c.130C> T (p.Pro44Ser) single nucleotide variant Uncertain significance rs796065315 GRCh38 Chromosome 11, 46701476: 46701476
15 ZNF408 NM_024741.2(ZNF408): c.130C> T (p.Pro44Ser) single nucleotide variant Uncertain significance rs796065315 GRCh37 Chromosome 11, 46723026: 46723026
16 ZNF408 NM_024741.2(ZNF408): c.402A> G (p.Gln134=) single nucleotide variant Uncertain significance rs561320549 GRCh38 Chromosome 11, 46702993: 46702993
17 ZNF408 NM_024741.2(ZNF408): c.694A> G (p.Met232Val) single nucleotide variant Uncertain significance rs796065316 GRCh37 Chromosome 11, 46725944: 46725944
18 ZNF408 NM_024741.2(ZNF408): c.402A> G (p.Gln134=) single nucleotide variant Uncertain significance rs561320549 GRCh37 Chromosome 11, 46724543: 46724543
19 ZNF408 NM_024741.2(ZNF408): c.694A> G (p.Met232Val) single nucleotide variant Uncertain significance rs796065316 GRCh38 Chromosome 11, 46704394: 46704394
20 ZNF408 NM_024741.2(ZNF408): c.1850C> A (p.Thr617Asn) single nucleotide variant Uncertain significance rs547169524 GRCh37 Chromosome 11, 46727100: 46727100
21 ZNF408 NM_024741.2(ZNF408): c.2145G> T (p.Glu715Asp) single nucleotide variant Uncertain significance rs796065317 GRCh38 Chromosome 11, 46705845: 46705845
22 ZNF408 NM_024741.2(ZNF408): c.2145G> T (p.Glu715Asp) single nucleotide variant Uncertain significance rs796065317 GRCh37 Chromosome 11, 46727395: 46727395
23 ZNF408 NM_024741.2(ZNF408): c.-111C> A single nucleotide variant Uncertain significance rs796065314 GRCh38 Chromosome 11, 46700937: 46700937
24 ZNF408 NM_024741.2(ZNF408): c.1850C> A (p.Thr617Asn) single nucleotide variant Uncertain significance rs547169524 GRCh38 Chromosome 11, 46705550: 46705550
25 ZNF408 NM_024741.2(ZNF408): c.-214_-210delGAATC deletion Uncertain significance rs796065313 GRCh38 Chromosome 11, 46700834: 46700838
26 ZNF408 NM_024741.2(ZNF408): c.-214_-210delGAATC deletion Uncertain significance rs796065313 GRCh37 Chromosome 11, 46722384: 46722388
27 LRP5 NM_002335.2(LRP5): c.3107G> A (p.Arg1036Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs61889560 GRCh37 Chromosome 11, 68191036: 68191036
28 LRP5 NM_002335.2(LRP5): c.3107G> A (p.Arg1036Gln) single nucleotide variant Conflicting interpretations of pathogenicity rs61889560 GRCh38 Chromosome 11, 68423568: 68423568
29 FZD4 NM_012193.3(FZD4): c.313A> G (p.Met105Val) single nucleotide variant Pathogenic rs80358284 GRCh38 Chromosome 11, 86952443: 86952443
30 FZD4 NM_012193.3(FZD4): c.313A> G (p.Met105Val) single nucleotide variant Pathogenic rs80358284 GRCh37 Chromosome 11, 86663485: 86663485
31 CTNNB1 NM_001904.3(CTNNB1): c.1434_1435insC (p.Glu479Argfs) insertion Pathogenic rs1057519379 GRCh38 Chromosome 3, 41233777: 41233778
32 CTNNB1 NM_001904.3(CTNNB1): c.1434_1435insC (p.Glu479Argfs) insertion Pathogenic rs1057519379 GRCh37 Chromosome 3, 41275268: 41275269
33 CTNNB1 NM_001904.3(CTNNB1): c.2128C> T (p.Arg710Cys) single nucleotide variant Pathogenic rs748653573 GRCh37 Chromosome 3, 41279558: 41279558
34 CTNNB1 NM_001904.3(CTNNB1): c.2128C> T (p.Arg710Cys) single nucleotide variant Pathogenic rs748653573 GRCh38 Chromosome 3, 41238067: 41238067
35 CTNNB1 NM_001904.3(CTNNB1): c.2142_2157dup (p.His720Terfs) duplication Pathogenic rs1057519380 GRCh37 Chromosome 3, 41280629: 41280644
36 CTNNB1 NM_001904.3(CTNNB1): c.2142_2157dup (p.His720Terfs) duplication Pathogenic rs1057519380 GRCh38 Chromosome 3, 41239138: 41239153
37 LRP5 NM_002335.3(LRP5): c.1199C> T (p.Ala400Val) single nucleotide variant Uncertain significance rs201320326 GRCh38 Chromosome 11, 68386499: 68386499
38 LRP5 NM_002335.3(LRP5): c.1199C> T (p.Ala400Val) single nucleotide variant Uncertain significance rs201320326 GRCh37 Chromosome 11, 68153967: 68153967
39 subset of 15 genes:DLG2; FZD4 NC_000011.9: g.83315294_86755595del3440302 deletion Pathogenic GRCh37 Chromosome 11, 83315294: 86755595
Sources

Expression for Exudative Vitreoretinopathy 1

About this section
Search GEO for disease gene expression data for Exudative Vitreoretinopathy 1.
Sources

Pathways for Exudative Vitreoretinopathy 1

About this section

Pathways related to Exudative Vitreoretinopathy 1 according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
Focal Adhesion 1 38
Show member pathways
 12.76 CTNNB1 FLT1 IGF1 KDR VEGFA
2
Ras signaling pathway 38
Show member pathways
 12.61 CTNNB1 FLT1 IGF1 KDR VEGFA
3
Pathways in cancer 38
12.61 CTNNB1 EPO FZD4 IGF1 LRP5 VEGFA
4
PI3K-Akt signaling pathway 38
Show member pathways
 12.53 CTNNB1 EPO FLT1 FZD4 IGF1 KDR
5
mTOR signaling pathway (KEGG) 38
Show member pathways
 12.3 FLT1 FZD4 IGF1 KDR LRP5
6
RhoGDI Pathway 65
Show member pathways
 12.27 ARHGAP1 FLT1 KDR VEGFA
7
Colorectal Cancer Metastasis 65
12.05 CTNNB1 FZD4 LRP5 VEGFA
8
SMAD Signaling Network 65
11.94 CTNNB1 FLT1 KDR VEGFA
9
S1P3 pathway 1
Show member pathways
 11.85 FLT1 KDR VEGFA
10
Glioblastoma Multiforme 65
11.83 CTNNB1 FZD4 IGF1
11
Reelin Pathway (Cajal-Retzius cells) 65
11.78 ARHGAP1 CTNNB1 FZD4 LRP5
12
HIF-1 signaling pathway 38
11.67 EPO FLT1 IGF1 VEGFA
13
Proteoglycans in cancer 38
11.66 CTNNB1 FZD4 IGF1 KDR VEGFA
14
Primary Focal Segmental Glomerulosclerosis FSGS 1
11.63 CDKN1C CTNNB1 LRP5
15
Transcription_P53 signaling pathway 23
11.58 CTNNB1 FLT1 KDR VEGFA
16
Endochondral Ossification 1
11.56 CDKN1C IGF1 VEGFA
17
Signaling events mediated by VEGFR1 and VEGFR2 1
Show member pathways
 11.52 CTNNB1 FLT1 KDR VEGFA
18
G-protein signaling_Regulation of RAC1 activity 23
11.48 ARHGAP1 CTNNB1 FZD4 LRP5
19
Differentiation Pathway 1
11.38 EPO IGF1 VEGFA
20
Vemurafenib Pathway, Pharmacodynamics 62
11.27 FLT1 KDR VEGFA
21
Cytoskeleton remodeling_RalB regulation pathway 23
10.96 ARHGAP1 FLT1 KDR VEGFA
22
Angiogenesis (WikiPathways) 1
10.88 FLT1 KDR VEGFA
23
HIF-2-alpha transcription factor network 1
10.46 EPO FLT1 KDR VEGFA
Sources

GO Terms for Exudative Vitreoretinopathy 1

About this section

Cellular components related to Exudative Vitreoretinopathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface GO:0009986 9.55 CD38 EPO FZD4 NDP VEGFA
2 Wnt signalosome GO:1990909 8.96 CTNNB1 LRP5
3 sorting endosome GO:0097443 8.62 ARHGAP1 KDR

Biological processes related to Exudative Vitreoretinopathy 1 according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.91 CTNNB1 IGF1 KDR VEGFA
2 angiogenesis GO:0001525 9.89 FLT1 KDR TSPAN12 VEGFA
3 positive regulation of cell migration GO:0030335 9.88 FLT1 IGF1 KDR VEGFA
4 kidney development GO:0001822 9.8 CDKN1C CTNNB1 VEGFA
5 positive regulation of MAPK cascade GO:0043410 9.8 CTNNB1 FLT1 IGF1 KDR
6 Wnt signaling pathway GO:0016055 9.8 CTNNB1 FZD4 LRP5 NDP TSPAN12
7 positive regulation of DNA-binding transcription factor activity GO:0051091 9.79 CTNNB1 FZD4 NDP
8 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.75 FLT1 IGF1 KDR
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.74 EPO IGF1 VEGFA
10 vascular endothelial growth factor receptor signaling pathway GO:0048010 9.73 FLT1 KDR VEGFA
11 negative regulation of apoptotic process GO:0043066 9.73 CD38 CTNNB1 EPO IGF1 KDR VEGFA
12 positive regulation of osteoblast differentiation GO:0045669 9.72 CTNNB1 IGF1 LRP5
13 canonical Wnt signaling pathway GO:0060070 9.67 CTNNB1 FZD4 LRP5 NDP
14 gastrulation with mouth forming second GO:0001702 9.63 CTNNB1 LRP5
15 positive regulation of vascular endothelial growth factor receptor signaling pathway GO:0030949 9.63 FLT1 VEGFA
16 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.63 FLT1 KDR VEGFA
17 cardiac muscle fiber development GO:0048739 9.61 TCAP VEGFA
18 positive regulation of mesenchymal cell proliferation GO:0002053 9.61 CTNNB1 LRP5 VEGFA
19 positive regulation of positive chemotaxis GO:0050927 9.6 KDR VEGFA
20 positive regulation of transcription, DNA-templated GO:0045893 9.56 CD38 CDKN1C CTNNB1 EPO FZD4 IGF1
21 retina vasculature morphogenesis in camera-type eye GO:0061299 9.54 FZD4 NDP
22 retinal blood vessel morphogenesis GO:0061304 9.52 FZD4 LRP5
23 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.51 KDR VEGFA
24 vascular endothelial growth factor signaling pathway GO:0038084 9.5 FLT1 KDR VEGFA
25 extracellular matrix-cell signaling GO:0035426 9.48 FZD4 NDP
26 vasculogenesis GO:0001570 9.46 CTNNB1 FZD4 KDR VEGFA
27 positive regulation of cell proliferation GO:0008284 9.23 CD38 CTNNB1 EPO FLT1 IGF1 KDR

Molecular functions related to Exudative Vitreoretinopathy 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 vascular endothelial growth factor-activated receptor activity GO:0005021 8.96 FLT1 KDR
2 Wnt-activated receptor activity GO:0042813 8.8 FZD4 LRP5 TSPAN12
3 protein binding GO:0005515 10.09 ARHGAP1 ATP7B CDKN1C CTNNB1 EPO FLT1
Sources

Sources for Exudative Vitreoretinopathy 1

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....